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Abstract
 
The mannose receptor (MR) is an endocytic protein on macrophages and dendritic cells, as well as
on hepatic endothelial, kidney mesangial, tracheal smooth muscle, and retinal pigment epithelial
cells. The extracellular portion contains two types of carbohydrate-recognition domain (CRD):
eight membrane-proximal C-type CRDs and a membrane-distal cysteine-rich domain (Cys-MR).
The former bind mannose-, 
 
N
 
-acetylglucosamine-, and fucose-terminating oligosaccharides, and
may be important in innate immunity towards microbial pathogens, and in antigen trapping for
processing and presentation in adaptive immunity. Cys-MR binds to the sulfated carbohydrate
chains of pituitary hormones and may have a role in hormonal clearance. A second feature of Cys-
MR is binding to macrophages in marginal zones of the spleen, and to B cell areas in germinal cen-
ters which may help direct MR-bearing cells toward germinal centers during the immune re-
sponse. Here we describe two novel classes of carbohydrate ligand for Cys-MR: chondroitin-4
sulfate chains of the type found on proteoglycans produced by cells of the immune system, and sul-
fated blood group chains. We further demonstrate that Cys-MR interacts with cells in the spleen
via the binding site for sulfated carbohydrates. Our data suggest that the three classes of sulfated car-
bohydrate ligands may variously regulate the trafficking and function of MR-bearing cells.
Key words: chondroitin sulfate • cysteine-rich domain • lutropin (luteinizing hormone) • 
macrophage receptor • sulfo-Lewis
 
a/x
 
Introduction
 
The mannose receptor (MR)
 
1
 
 is a type I transmembrane
protein with an extracellular portion consisting of eight
membrane-proximal C-type carbohydrate-recognition do-
mains (CRDs), followed by a domain containing a fi-
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Abbreviations used in this paper:
 
 CRD, carbohydrate-recognition domain;
CS, chondroitin sulfate; Cys-MR, cysteine-rich domain of the MR;
 
D
 
UA, 4,5-unsaturated uronic acid; ECM, extracellular matrix; Hex, hex-
ose; HexNAc, 
 
N
 
-acetylhexosamine; IC
 
50
 
, half-maximal inhibitory con-
centration; Ii, invariant chain; LNNT, lacto-
 
N
 
-neotetraose; LSIMS, liq-
uid secondary ion mass spectrometry; MR, mannose receptor; NGL,
neoglycolipid; pLH, porcine lutropin (luteinizing hormone); 3S-Le
 
a
 
, 3
 
9
 
-
sialyl-Lewis
 
a
 
; 3S-Le
 
x
 
, 3
 
9
 
-sialyl-Lewis
 
x
 
; 3Su-Le
 
a
 
, 3
 
9
 
-sulfated-Lewis
 
a
 
; 3Su-
Le
 
x
 
, 3
 
9
 
-sulfated-Lewis
 
x
 
; 6Su-Le
 
x
 
, 6
 
9
 
-sulfated-Lewis
 
x
 
; 3Su-LNNT, 3
 
9
 
-sul-
fated-LNNT; TBS, Tris-buffered saline. 
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bronectin type II repeat, and a membrane-distal cysteine-
rich domain (Cys-MR; references 1, 2). MR was originally
identified on macrophages, but it was also expressed on
dendritic cells, hepatic endothelial cells, tracheal smooth
muscle cells, retinal pigment epithelium, kidney mesangial
cells, and Kaposi sarcoma cells (3). MR is a carbohydrate-
recognizing receptor that binds to mannose, fucose, and
 
N
 
-acetylglucosamine via the CRDs (4). The CRDs mediate
binding to a variety of polysaccharides such as those at the
surface of pathogenic microorganisms, and the receptor has
endocytic and phagocytic properties conferred by the cyto-
plasmic domain. These features render MRs important for
macrophage uptake of bacteria, yeasts, and parasites, and
thereby may contribute to innate immunity toward these
pathogens (3). The endocytic function of MR is also im-
portant in adaptive immunity, namely, in the uptake of an-
tigens by immature dendritic cells and their delivery to
MHC class II compartments for antigen processing and
presentation (5). The CRDs are not the only lectin do-
mains on MR. The Cys-MR has been shown to bind to
the sulfated carbohydrate chains of the pituitary hormones,
lutropin, and thyroid-stimulating hormones (6–9). The
recognition motif is on the 4-sulfated 
 
N
 
-acetylgalac-
tosamine–terminating sequence GalNAc(4S)
 
b
 
1-4GlcNAc
 
b
 
1-2Man, which occurs on the 
 
N
 
-glycans of these glyco-
proteins (10). It has been proposed (11) that Cys-MR on
hepatic endothelial cells has a role in the rapid clearance of
lutropin from the serum, which is important for maintain-
ing hormone responsiveness in vivo. There is recent evi-
dence that additional binding of lutropin, and also thy-
rotropin, occurs via nonsulfated carbohydrate domains to
the CRDs of MR (12). A recombinant, soluble form of
Cys-MR has been shown to bind to metallophilic mac-
rophages in the marginal zones of the spleen, and in the
subcapsular sinuses of lymph nodes, to cells in B cell areas,
some with dendritic morphology in nascent germinal cen-
ters. It has also been proposed that the Cys-MR may help
to direct MR-bearing cells toward germinal centers during
immune responses (13). Moreover, macrophages secrete a
soluble form of MR, which may have a role in binding to
and directing mannose-bearing antigens to cells bound by
Cys-MR at sites where humoral immune responses are or-
chestrated (13, 14).
In the course of performing carbohydrate-recognition
studies on the cysteine-rich domain (Cys-DEC) of the
dendritic cell receptor (DEC-205), a transmembrane pro-
tein with a modular architecture similar to MR (15), we
carried out parallel carbohydrate-binding experiments with
Cys-MR. We found a lack of Cys-DEC binding to
lutropin, but identified two additional types of sulfated car-
bohydrate recognition elements for Cys-MR. Here we de-
scribe glycosaminoglycan sequences of chondroitin sulfate
type, and also sulfated oligosaccharide sequences of the
blood group Lewis
 
x
 
 (Le
 
x
 
) and Le
 
a
 
 series, which are recog-
nized by Cys-MR, and provide evidence for the existence
of a wider range of counterreceptors than hitherto antici-
pated for the multifunctional MR.
 
Materials and Methods
 
Recombinant Soluble Cysteine-rich Domain of the Macrophage MR.
 
A soluble form of the cysteine-rich domain of the murine macro-
phage mannose receptor (Cys-MR) fused to the Fc domain of
human IgG (Cys-MR-Fc) was expressed and purified as de-
scribed (13). Cys-DEC-Fc is a fusion protein containing the cys-
teine-rich domain of DEC-205 (15) and the Fc domain of human
IgG. A spacer consisting of ESG was placed between the GPY-
HEI at the end of the Cys-DEC and IgG. Cys-DEC-Fc was ex-
pressed and purified exactly as described for Cys-MR-Fc.
 
Glycoproteins, Proteoglycans, and Polysaccharides.
 
Highly purified
porcine lutropin (pLH SD477, 2.0
 
3
 
 LH NIH S1) was prepared
essentially as described (16). Human lutropin (hLH), chondroitin
sulfate A (CS-A, from bovine trachea containing 30% of CS-C),
CS-B (from porcine intestinal mucosa containing 10% of CS-A
and -C), CS-C (from shark cartilage containing 10% of CS-A),
and heparin (from porcine intestinal mucosa) were from Sigma
Chemical Co.
CS proteoglycans were isolated from the conditioned, serum-
free medium of the cultured monocytic cell line, THP-1 (17). In
brief, the conditioned medium was subjected twice to Q-Seph-
arose anion-exchange chromatography. After extensive washing,
the bound molecules were eluted with a gradient of 0.35–1.5 M
NaCl in 0.5 M NaOAc, 6 M urea, pH 6.0. The proteoglycan-
containing fractions, detected by safranin O staining (18), were
pooled and desalted on a Sephadex G-50 (fine) column. After la-
beling with 
 
125
 
I, the purified material was treated with chon-
droitinase ABC (Sigma Chemical Co.), and subjected to SDS-
PAGE. A major band of 
 
z
 
14 kD appeared, consistent with the
core protein of serglycin. The identity of the protein was con-
firmed by NH
 
2
 
-terminal amino acid sequencing.
 
Oligosaccharides.
 
The sequences of the oligosaccharides inves-
tigated in this study are shown in Table I.
 
Sulfated N-Glycan from pLH.  N
 
-glycans from 100 mg pLH
were released by hydrazinolysis followed by re–
 
N
 
-acetylation
(19). The solution was then desalted with 25 ml AG50W-X12
resin (H
 
1
 
 form; Bio-Rad Laboratories) and freeze dried. Peptides
were removed on a TSK Amide-80 (TosoHaas) HPLC column
(4.6 
 
3
 
 250 mm) using a gradient of 80–20% acetonitrile in 2.5
mM trifluoroacetic acid and 10 mM NH
 
4
 
OAc, pH 4.5 (solvent A
and B, respectively) at a flow rate of 1 ml/min. Aliquots contain-
ing 
 
z
 
200 
 
m
 
g hexose were dissolved in and run for 3 min in 65%
solvent A and 35% solvent B. A linear gradient rising to 75% sol-
vent B was applied for 3 min, and the gradient was maintained for
2 min before decreasing to 35% solvent B. Under these condi-
tions, oligosaccharides eluted between 6 and 11 min. Oligosac-
charides containing 
 
z
 
2 mg hexose were recovered from 100 mg
of pLH. These were fractionated by gel filtration chromatography
on a Bio-Gel P-6 column (1.6 
 
3
 
 90 cm), eluted with 0.2 M am-
monium acetate at 15 ml/h, and monitored using a refractive in-
dex detector. A peak designated F3 (834 
 
m
 
g hexose) contained
mainly monosulfated monoantennary 
 
N
 
-glycans as judged by liq-
uid secondary ion mass spectrometry. The [M-H]
 
2
 
 ion at m/z
1,541 corresponds to a composition of HSO
 
3
 
.Hex
 
3
 
.HexNAc
 
4
 
.
dHex
 
1 
 
(where Hex is a hexose, HexNAc is an 
 
N
 
-acetylhex-
osamine, and dHex is deoxyhexose [fucose]), and m/z 1,395 cor-
responds to HSO
 
3
 
.Hex
 
3
 
.HexNAc
 
4
 
. These are consistent with
the sequence HSO
 
3
 
-GalNAc-GlcNAc-Man-(Man)Man-GlcNAc-
GlcNAc with or without fucose (10). Small amounts of bianten-
nary sulfated 
 
N
 
-glycans were also present, as indicated by the
[M-H]
 
2
 
 ions at m/z 1,801 (HSO
 
3
 
.Hex
 
3
 
.HexNAc
 
6
 
) and 1,881
([HSO
 
3
 
]
 
2
 
.Hex
 
3
 
.HexNAc
 
6
 
). Fraction F3 was further chromato- 
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graphed on an APS-2 (Hypersil, Astmoor) HPLC column (5 
 
m
 
m,
4.6 mm 
 
3
 
 250 mm; Phenomenex) with monitoring at 206 nm.
Elution was carried out with a linear gradient of NaH
 
2
 
PO
 
4
 
 (sol-
vent C, 5 mM NaH
 
2
 
PO
 
4
 
 and solvent D, 50 mM NaH
 
2
 
PO
 
4
 
, from
10 to 50% solvent D in 40 min) at a flow rate of 1 ml/min. The
major peak designated F3-2 was pooled, freeze dried, and de-
salted on a Sephadex G-10 column (1.6 
 
3
 
 36 cm). This in turn
gave exclusively the two [M-H]
 
2
 
 ions at m/z 1,541 and 1,395
noted above. The oligosaccharide sequence in F3-2 was corrobo-
rated by the molecular ions and fragment ions of the derived
neoglycolipids (NGLs; Fig. 1). The molecular ions at m/z 2,188
and 2,042 together with their sodiated ions at m/z 2,210 and
2,064 are consistent with those of NGLs of a sulfated monoanten-
nary 
 
N
 
-glycan with and without a fucose residue. The fragment
ion at m/z 2,108 corresponds to the loss of HSO
 
3
 
. In part, m/z
2,042 represents a fragment ion resulting from loss of the dHex.
The fragment ion at m/z 1,905 corresponds to the loss of HSO
 
3
 
.
HexNAc; m/z 1,702, loss of HSO
 
3
 
.HexNAc.HexNAc; m/z
1,540, loss of HSO
 
3
 
.HexNAc.HexNAc.Hex; m/z 1,216, loss of
HSO
 
3
 
.HexNAc.HexNAc.Hex
 
3
 
; and m/z 1,013, loss of HSO
 
3
 
.
HexNAc.HexNAc.Hex
 
3
 
.HexNAc. This spectrum is consistent
with the monoantennary 
 
N
 
-glycan with and without a core fu-
cose residue described as one of the major oligosaccharides on
LH (10).
 
CS Oligosaccharides. 
 
Pentasaccharide fragments from CS-A,
CS-B, and CS-C were prepared and purified essentially as de-
scribed previously (20). In brief, the CS chains were partially de-
polymerized by limited digestion with chondroitinase ABC (EC
4.2.2.4, from 
 
Proteus vulgaris
 
; Sigma Chemical Co.) to generate
oligosaccharides consisting of even-numbered monosaccharide
residues with a terminal unsaturated uronic acid (
 
D
 
UA) residue.
These were chromatographed on a Bio-Gel P-6 column. The
hexasaccharide fractions were subjected to oxymercuration treat-
ment (20, 21) to remove the 
 
D
 
UA residues, and the resulting
pentasaccharides were isolated by gel filtration on a Sephadex
G-10 column. Quantitation was carried out by the carbazole assay
(22) using 
 
d
 
-glucurono-6,3-lactone as a standard. The predomi-
nant sequences in the three pentasaccharides designated CS-A5,
CS-B5, and CS-C5 (shown in Table I) were deduced by HPLC
disaccharide-composition analysis after chondroitinase ABC di-
gestion of the parent hexasaccharides (23).
 
Monosaccharides and Blood Group Oligosaccharides. 
 
The monosac-
charides, 4-sulfated GalNAc, 6-sulfated GalNAc, and 4,6-disul-
fated GalNAc were from Sigma Chemical Co. Lacto-
 
N
 
-neotet-
raose (LNNT) was from Dextra. 3
 
9
 
-sialyl-Lewis
 
a
 
 pentasaccharide,
3S-Le
 
a
 
, was from the Institute of Food Substances (Moscow). The
following oligosaccharides were synthesized chemically: 3
 
9
 
-sialyl-
Lewisx pentasaccharide, 3S-Lex (24); 39-sulfated-Lex pentasaccha-
ride, 3Su-Lex (25); 39-sulfated-Lea pentasaccharide, 3Su-Lea (26);
and 69-sulfated-Lex pentasaccharide, 6Su-Lex (25). The 39-sulfated-
lacto-N-tetraose, 3Su-LNT, and 39-sulfated-LNNT, 3Su-LNNT,
were prepared by mild acid hydrolysis (27) of 3Su-Lea and 3Su-Lex,
respectively.
NGLs. NGLs, unless otherwise stated, were prepared by the
conjugation of oligosaccharides to the aminophospholipid L-1,2-
dihexadecyl-sn-glycero-3-phosphoethanolamine (DHPE; Fluka),
followed by isolation from the reaction mixtures by TLC as de-
scribed previously (28). A modified procedure was used for the
preparation of NGLs from CS oligosaccharides. In brief, ly-
ophilized CS oligosaccharides (100 nmol) were dissolved in 5 ml
H2O, and 100 ml of DHPE solution (5 mg/ml in CHCl3/MeOH
1:3, vol/vol) was added, followed by 20 ml of freshly prepared
tetrabutylammonium cyanoborohydride (20 mg/ml in MeOH).
The reaction mixtures were heated at 608C for 70 h, conjugation
was monitored by high performance TLC, and NGLs were puri-
fied using silica minicolumns (500 mg silica, Sep-Pak® Vac Car-
tridge; Waters Corp.) essentially as described previously (29).
Biotinylated Oligosaccharides. Oligosaccharides were conju-
gated to 6-(biotinyl)-aminocaproyl-hydrazide (BACH; Sigma
Chemical Co.) and characterized as described previously (30, 31).
In brief, the oligosaccharides were reacted with BACH for 16 h
in methanol/water 95:5, vol/vol, purified by HPLC, and its
chemical structures were corroborated by mass spectrometry.
Liquid Secondary Ion Mass Spectrometry. Negative-ion liquid
secondary ion mass spectrometry (LSIMS) was carried out on a
VG Analytical ZAB-2E mass spectrometer (VG Analytical)
equipped with a cesium ion gun operated at 25 keV with an
emission current of 0.5 mA. For the native and biotinylated oli-
gosaccharides,  z1  mg of sample was used for analysis with
thioglycerol as the liquid matrix. NGLs were analyzed by in situ
TLC/LSIMS with a mixture of diethanolamine/tetramethylurea/
m-nitrobenzyl alcohol (2:2:1, by volume) as the matrix as de-
scribed previously (32).
Binding Experiments. Binding of Cys-MR-Fc or of Cys-
DEC-Fc, 0.5 mg/well (preincubated with anti–human IgG, at a
chimera to anti-IgG ratio of 1:3 [wt/wt]) to glycoproteins or to
NGLs (reaction volumes 50 ml), was assayed essentially as de-
scribed previously for L-selectin (33). For inhibition of Cys-MR
binding to hLH (0.5 mg hLH added/well), the Cys-MR-Fc was
used at 0.25 mg/well, which gave an absorbance in the range of
0.75–0.79 corresponding to 50% of maximum absorbance. Cys-
MR binding was also examined to serglycin immobilized on mi-
crowells (1.5 mg added/well) and treated at 308C for 4 h with
either chondroitinase ABC (50 mU in 50 ml of 10 mM phosphate
buffer, 150 mM NaCl, pH 7.5 [PBS]), with the heat-denatured
enzyme, with heparinase I (2.5 U), or with PBS alone. After
washing four times with PBS, binding of Cys-MR-Fc, 0.5 mg
added/well, was assayed as above.
Figure 1. Mass spectrum of the NGLs derived
from the sulfated N-glycan, pLH-F3-2, isolated
from lutropin. The molecular ions and fragment
ions correspond to those of the monoantennary
N-glycan sequence illustrated, with and without a
core fucose residue, which was described previ-
ously as one of the major oligosaccharide species in
human lutropin (reference 10).1120 Macrophage Receptor Binds Chondroitin 4-Sulfate Chains
Binding of Cys-MR-Fc to biotinylated oligosaccharides was
assayed essentially as described previously for plant lectins (30)
and selectins (31). In brief, biotinylated oligosaccharides were im-
mobilized in high capacity streptavidin-coated microtiter wells
(Boehringer Mannheim) in TBS (10 mM Tris-HCl buffer, pH
8.0, 150 mM NaCl). Cys-MR-Fc chimera was at 5 mg/well (pre-
incubated for 1 h with rabbit anti–human IgG, at a chimera to
anti-IgG ratio of 1:3 [wt/wt]). The diluent used was TBS con-
taining 0.5% (wt/vol) BSA, and reaction volumes were 200 ml.
Binding was detected with peroxidase-labeled protein A (10 mg/
ml) using ABTS (2,29-azinobis[3-ethylbenzthiazoline-sulfonic
acid]) as substrate, and absorbance was read at 405 nm.
Histochemical Experiments. Histochemical staining of spleens
from nonimmunized C57 mice and mice 9–10 d after intraperito-
neal immunization with 100 mg of chicken gammaglobulin pre-
cipitated in alum (Jackson ImmunoResearch Laboratories) was
performed essentially as described (13). In brief, 8-mm cryostat
sections were fixed for 12 min in acetone at 48C or in 2% formal-
dehyde in PBS at 188C. Fixed sections were washed in PBS, and
Fc receptors were blocked for 10 min at 188C using rat anti–
mouse CD16/CD32 (Becton Dickinson) at 10 mg/ml in 5%
(vol/vol) donkey serum-PBS. Sections were incubated for 30
min at 188C with the Cys-MR-Fc chimera at 10 mg/ml in don-
key serum-PBS. Binding was detected using fluorescein-labeled
donkey anti–human IgG (Jackson ImmunoResearch Laborato-
ries) for 30 min at 188C, and sections were viewed with a Zeiss
ultraviolet epifluorescence microscope. Specificity of staining was
corroborated by the lack of staining of sections similarly incu-
bated with a recombinant human Fc dimer (gift of Dr. E. Hofer,
University of Vienna, Vienna, Austria). B cell areas in the splenic
white pulp were identified by staining with rat anti–mouse com-
plement receptor type 1 (CD35; Becton Dickinson) at 10 mg/ml.
Antibody binding was detected using rhodamine-labeled donkey
anti–rat IgG (Jackson ImmunoResearch Laboratories).
In certain experiments, the fixed spleen sections were treated
for 30 min at 378C with chondroitinase ABC (500 mU/ml) or
with heparinase I (100 mU/ml) diluted in PBS containing 0.05%
(vol/vol) Tween 20 and 1 mM PMSF (Sigma Chemical Co.).
Enzyme-treated sections were stained in both single and dual im-
munolabeling experiments with a rabbit antiserum (1:100 dilu-
tion) specific for the core regions of cleaved CS chains (Biogene-
sis Ltd.) and with the Cys-MR-Fc. Binding of the CS antibody
was detected using rhodamine-labeled donkey anti–rabbit IgG
(Jackson ImmunoResearch Laboratories). The staining patterns
for the Cys-MR-Fc and the CS antibody were viewed simulta-
neously with a Zeiss LSM 510 confocal microscope, and apparent
colocalization in selected areas was confirmed by Z sectioning.
For inhibition studies, Cys-MR-Fc was incubated for 1 h at
188C with the monosaccharides GalNAc, 4-sulfated GalNAc, or
6-sulfated GalNAc (Sigma Chemical Co.) at 5 mg/ml before ap-
plication onto spleen sections.
Results
In accord with previous data, the Cys-MR-Fc gave a
binding signal with lutropin. In contrast, no binding was
detected with Cys-DEC (Fig. 2 A, inset). The NGL de-
rived from the sulfated N-glycan, F3-2, isolated from
lutropin was also strongly bound by Cys-MR-Fc (Fig. 2
A). As the Cys-MR binding was inhibitable with 4-sulfated
N-acetylgalactosamine (concentration giving 50% inhibi-
tion of binding [IC50] 0.18 mM), and less strongly with
6-sulfated and 4,6-disulfated N-acetylgalactosamine (IC50
values 1.34 and 0.85 mM, respectively; Fig 3 A), we exam-
ined the protein for recognition of glycans with various
sulfation patterns as described below, and see Table I.
Cys-MR Recognition of Chondroitin 4-Sulfate Sequences.
Initial inhibition of binding experiments with the commer-
cially available chondroitin sulfates, CS-A, CS-B and CS-C,
and heparin (Fig. 3 B) revealed an inhibitory activity in the
sample of CS-B. This inhibitor consists predominantly of
the repeating disaccharide sequence of 4-sulfated N-acetyl-
galactosamine [GalNAc(4S)] joined by b1-4 linkage to
iduronic acid (IdoA) as follows: [-3GalNAc(4S)b1-4IdoA
b1-]n. There was negligible inhibition by the CS-C polysac-
charide, which contained predominantly 6-sulfated N-ace-
tylgalactosamine [GalNAc(6S)] joined by b1-4 linkage to
glucuronic acid (GlcA): [-3GalNAc(6S)b1-4GlcAb1-]n, and
by heparin, which contain predominantly N- and 6-disul-
Figure 2. Binding experiments with Cys-MR and Cys-DEC. NGLs
(A–C), lutropin (A, inset), and biotinylated oligosaccharides (D) were im-
mobilized on microwells, and the binding of Cys-MR-Fc or Cys-DEC-
Fc, 5 mg/well, was assayed as described in Materials and Methods.
Figure 3. Inhibition of the binding of Cys-MR to lutropin by sulfated
monosaccharides and glycosaminoglycans. hLH, 0.5 mg/well, was coated
onto microwells, and the binding of Cys-MR-Fc, 0.25 mg/well, in the
presence of the sulfated monosaccharides (A) or glycosaminoglycans (B),
was assayed as described in Materials and Methods.1121 Leteux et al.
fated glucosamine [GlcNS(6S)] joined by b1-4 linkage to
2-sulfated iduronic acid: [-4GlcNS(6S)b1-4IdoA(2S)a1-]n.
The CS-A polysaccharide also gave negligible inhibition
despite the fact that it contains predominantly GalNAc(4S),
joined by b1-4 linkage to glucuronic acid: [-3GalNAc(4S)
b1-4GlcAb1-]n. Knowing the heterogeneity of sequences,
and of the terminal monosaccharides in glycoconjugates,
we prepared structurally defined oligosaccharides (Table I)
from the three CS polysaccharides, and evaluated their
NGLs for binding by Cys-MR.
The NGLs of the CS-B and CS-A pentasaccharides, CS-
B5 and CS-A5, were bound by Cys-MR-Fc (Fig. 2, A and
B). These pentasaccharides have a common terminal Gal-
NAc(4S) (Table I). In contrast to the pentasaccharide, the
CS-A hexasaccharide, CS-A6, which terminates with the
unsaturated uronic acid, DUAb1-3, did not give a detect-
able binding signal with Cys-MR-Fc despite the presence
of three GalNAc(4S) residues along the oligosaccharide
chain (Table I). First, these results show that Cys-MR rec-
ognizes GalNAc(4S) in a terminal (nonreducing end),
rather than an internal position. Therefore, the lack of in-
hibitory activity in the original sample of CS-A polysaccha-
ride suggests that the amount of terminal GalNAc(4S) is
likely to be lower than in the CS-B polymer. Second, the
carbohydrate-binding site of Cys-MR can accommodate
Figure 4. Immunofluorescence micrographs of sections of naive mouse
spleen showing inhibition of Cys-MR binding in the presence of sulfated
monosaccharides. Sections were overlaid with Cys-MR-Fc, 10 mg/ml, in
the presence of PBS (A), 4-sulfated N-acetylgalactosamine (B), 6-sulfated
N-acetylgalactosamine (C), or N-acetylgalactosamine (D), 5 mg/ml, and
binding was detected with fluorescein-labeled donkey anti–human IgG as
described in Materials and Methods. A9–D9 are the corresponding phase–
contrast micrographs. Similar results were obtained using spleen sections
from immunized mice (not shown). Original magnifications: 3650.
Table I. Oligosaccharides Investigated and Their Cys-MR Binding 
Strengths
*Binding strengths in the microwell assays, in which both the Cys-MR
and the immobilized saccharides were in an oligometric state, are arbi-
trarily scored here as 111; 11; 1; and 2. These symbols denote
binding signals (ODs at 405 nm) of 0.5 or more; 0.2–0.4; ,0.2; and 0,
respectively, using the NGLs at 100 pmol or the biotinylated oligosac-
charides at 10 pmol/well.
‡The predominant sequences are shown. From the disaccharide com-
position analysis of the parent hexasaccharides, it is deduced that CS-
A5 contains GalNAc(4S), 60%; CS-B5 contains GalNAc(4S), 90%; and
CS-C5 contains GalNAc(6S), 85%.1122 Macrophage Receptor Binds Chondroitin 4-Sulfate Chains
oligosaccharides terminating with GalNAc(4S) joined by
b1-4 linkage to glucuronic acid or iduronic acid, as well as
to  N-acetylglucosamine, as found on the N-glycans of
lutropin. The CS-C pentasaccharide, CS-C5, containing
predominantly the terminal GalNAc(6S)b1-4GlcAb1-3 se-
quence (Table I), gave a negligible binding signal with
Cys-MR-Fc, in accordance with the weak inhibitory ac-
tivity of the monosaccharide GalNAc(6S) relative to Gal-
NAc(4S).
Cys-MR Recognition of Sulfated Blood Group Chains. We
evaluated Cys-MR binding to the NGLs and biotinylated
forms of sulfated oligosaccharides of the blood group series,
based on the type 1 and type 2 backbone sequences with
galactose joined by b1-3 and b1-4 linkage to N-acetylglu-
cosamine: Galb1-3GlcNAc and Galb1-4GlcNAc, respec-
tively (Fig. 2, A, C, and D). Clearly, there is recognition of
sulfated forms of both types of blood group chains when
there is sulfate at position 3 of the terminal galactose.
Moreover, there is binding to the corresponding sulfated
Lea and Lex sequences, which contain fucose joined by a1-4
and a1-3 linkage to the N-acetylglucosamine of the type 1
and type 2 backbones, respectively. Overall, there is a pref-
erence for the type 2 analogues over the type 1, and for the
nonfucosylated chains over the fucosylated forms. There
was no detectable binding to the 6-sulfated-Lex sequence,
or to the 3S-Lea and 3S-Lex sequences.
Inhibition by Sulfated N-Acetylgalactosamine of the Cys-MR
Binding to Cells in the Spleen. Cys-MR-Fc showed strong
staining of large cells with granular cytoplasm in the mar-
ginal zone of spleen from naive and immunized mice, as
described previously by Martínez-Pomares et al. (13; Fig. 4
A). There were weaker punctate staining of groups of cells
in the splenic white pulp within B cell areas (Fig. 5 B),
which were identified by their strong staining with anti-
CD35. Staining by Cys-MR-Fc of cells in this region was
greater in immunized mice. There was no staining of
spleen sections from naive or immunized mice when simi-
larly incubated with the recombinant human Fc dimer (re-
sults not shown).
The Cys-MR-Fc staining of naive and immunized
mouse spleen was completely inhibited in the presence of
4-sulfated N-acetylgalactosamine (Fig. 4 B), markedly di-
minished in the presence of the 6-sulfated analogue (Fig. 4
C), but unaffected in the presence of the nonsulfated N-ace-
tylgalactosamine (Fig. 4 D).
Distribution of CS Immunostaining and Cys-MR Binding in
the White Pulp of Spleen, and Binding of Cys-MR to Proteogly-
cans Secreted by Monocytes. As cells of the immune system
are known to produce cell-associated and secreted forms of
CS proteoglycans, the amounts and proportions of which
may change after various stimuli (34–36), we compared the
immunostaining pattern for CS chains with that of Cys-
Figure 5. Confocal images of a dual im-
munolabeling experiment showing the sim-
ilar distribution and limited colocalization of
the binding of Cys-MR and an antibody to
the core regions of CS chains within the B
cell areas of the splenic white pulp. Before
immunolabeling, spleen sections from im-
munized mice were treated with chon-
droitinase ABC as described in Materials
and Methods. The sections were thereafter
overlaid with a rabbit antiserum, directed at
the core region of cleaved CS chains, and
Cys-MR-Fc, followed by rhodamine-
labeled anti–rabbit IgG (anti-CS binding, A)
and fluorescein-labeled anti–human IgG
(Cys-MR binding, B). The two staining
patterns are shown superimposed in C. The
area within the white square in C is shown
enlarged in D. Original magnifications: (A–
C) 32,000; (D) 310,000.1123 Leteux et al.
MR staining. In both naive and immunized mice, there
was similar distribution of the staining for CS chains and
Cys-MR binding within the B cell area of the white pulp
(Fig. 5, A and B), but they differed in the marginal zone
(not shown). There was no fluorescein staining observed
after incubation of sections with the recombinant human
Fc dimer (not shown); in addition, there was no rhodamine
staining observed in the absence of the antibody to CS (not
shown). Although similar, the two staining patterns for
Cys-MR-Fc and anti-CS in the B cell area overlapped only
in limited areas (yellow areas in Fig. 5, C and D). More-
over, there was no perceptible difference in the Cys-MR
staining in these areas before and after treatment with
chondroitinase ABC (results not shown). Thus, although
substantial amounts of CS chains are present, it is likely that
the Cys-MR binding forms are relatively minor compo-
nents.
To directly evaluate the ability of Cys-MR to interact
with chondroitin 4-sulfate proteoglycans produced by cells
of the hematopoietic and immune systems (34–37), we ex-
amined its binding to a preparation of proteoglycans se-
creted by a monocytic cell line and known to be rich in
serglycin. There was specific binding to the proteoglycan
immobilized  on microwells (Fig. 6), and treatment with
chondroitinase ABC, but not heparinase, abolished the
binding. We conclude that Cys-MR interacts with these
soluble proteoglycans via CS chains.
Discussion
Here we establish that the ligands of Cys-MR encompass
two classes of oligosaccharide chains additional to the de-
scribed previously (10) N-glycans on pituitary hormones,
which terminate in 4-sulfated N-acetylgalactosamine b1-4
linked to N-acetylglucosamine. The additional classes of
ligands include sulfated glycosaminoglycans and sulfated
blood group chains. The glycosaminoglycans strongly
bound are of chondroitin 4-sulfate type having in common
a terminal 4-sulfated N-acetylgalactosamine that is joined
by b1-4 linkage to iduronic acid (CS-B) or to glucuronic
acid (CS-A). In the sulfated blood group chains that are
bound by Cys-MR, there is a terminal 3-sulfated galactose
b1-4 or b1-3 linked to N-acetylglucosamine.
The mechanism whereby the Cys-MR can accommo-
date the three classes of oligosaccharide ligand is elucidated
by the structural study of the Cys-MR complexed with
4-sulfated N-acetylgalactosamine (38). The crystal structure
shows that the sulfate group is involved in no less than six
hydrogen bonds with the protein; the N-acetyl group has
no contact, however, with the binding site of Cys-MR.
This explains our finding that a sulfated galactose can be
bound as well as a sulfated N-acetylgalactosamine. A struc-
tural explanation is also provided for the weak inhibitory
activity we have observed in the present investigation for
the 6-sulfated N-acetylgalactosamine (IC50 1.3 mM) com-
pared with that for the 4-sulfated form (IC50 0.18 mM).
Molecular modeling by Liu et al. (38) based on the crystal
structure shows that for optimum binding, the sulfate
group must be at C-3 or C-4 of the terminal monosaccha-
ride. When GalNAc is sulfated at C-6, it does not make
favorable van der Waals contacts with Trp117 of the Cys-
MR binding site. The modeling studies also show that the
addition of a monosaccharide at C-3 of the 4-sulfated
N-acetylgalactosamine would hinder the binding of the sul-
fate. This accounts for our observation that the hexasac-
charide CS-A6 with a terminal uronic acid linked to C-3
of N-acetylgalactosamine was not bound by Cys-MR. We
can now also explain the preferential binding of Cys-MR
to the 3Su-Lex over the 3Su-Lea analogue. The modeling,
based on the crystal structure, shows that the sulfated ga-
lactose and the fucose of Lex can be stacked readily against
Trp117, whereas in the Lea analogue, there is steric hin-
drance between the N-acetyl group and Asn102 in the
Cys-MR binding site.
In contrast to Cys-MR, the cysteine-rich domain of
DEC-205, another member of the MR family, did not
give a binding signal with lutropin in the present investi-
gation. The structural basis for this finding is apparent
from the x-ray crystallographic study of the Cys-MR–
ligand complex by Liu et al. (38) which defines the amino
acid residues used to bind the sulfated carbohydrates. The
amino acids in the analogous region are lacking in the
Cys-DEC sequence.
A new finding in the present investigation is that the
binding described for Cys-MR with cells both in the mar-
ginal zones and in the B cell areas of the naive and the im-
mune spleen (13) is mediated by the binding site for sul-
fated carbohydrates. We further provide evidence that
Cys-MR binds secreted proteoglycans of cells of the im-
mune system, the major component of which is serglycin
(36). Binding to serglycin is via the CS chains, which are
known to be predominantly of chondroitin 4-sulfate type
(37).
Serglycin accumulates in intracellular vesicles of cells of
the immune system, and is secreted by the activated cells
(36). The amounts of such proteoglycans that are retained
in cells, or are secreted, differ after various stimuli (39).
Thus, in lymphoid tissues in vivo, the serglycin has the po-
tential to form a complex with Cys-MR and modulate the
availability of the saccharide-binding site of both the trans-
membrane form and the secreted form of MR. It has been
Figure 6. Binding of Cys-MR
to serglycin and abolition of
binding after treatment of the
proteoglycan with chondroiti-
nase ABC but not heparinase.
Serglycin was coated onto mi-
crowells, 1.5 mg added/well, and
incubated with chondroitinase
ABC (50 mU), the heat-dena-
tured chondroitinase ABC, hep-
arinase I (2.5 U), or PBS. The
binding of Cys-MR-Fc, 0.5 mg/
well, was assayed as described in
Materials and Methods.1124 Macrophage Receptor Binds Chondroitin 4-Sulfate Chains
shown recently (17) that serglycin in the serum is rapidly
taken up by hepatic endothelial cells (also referred to as si-
nusoidal scavenger endothelial cells), and that a hyaluronan
receptor plays a major role in the uptake. We propose that
interactions of Cys-MR with serglycin in lymphatic tissue
fluid, or with serglycin in homogenates of hepatic cells,
may underlie the reported lack of demonstrable binding ac-
tivity of certain tissue isolates of MR toward sulfated oli-
gosaccharides (8).
Chondroitin 4-sulfate chains occur also on cell mem-
brane–associated proteoglycans of lymphocytes, mono-
cytes, macrophages, and other cells of the hematopoietic
system (34). Changes in their carbohydrate chains have
been documented during cellular activation (36). Notable
among chondroitin 4-sulfate–containing proteoglycans at
the cell surface are several variants of the signal-transducing
molecule CD44 (40). It will be interesting to investigate if
such glycosylation variants of CD44 are among counter-
receptors for the Cys-MR.
An intriguing candidate counterreceptor for Cys-MR is
the CS-modified form of the class II invariant chain (Ii) re-
ferred to as Ii-CS. While Ii-CS amounts to only a small
proportion (2–5%) of Ii that associates with newly synthe-
sized class II, it appears nevertheless to have an important
role in antigen presentation functions (41). Evidence has
been presented that expression of Ii-CS in antigen-present-
ing cells enhances antigen presentation and thereby en-
hances the triggering of primary antigen responses by T
cells (41). Knowing that an abundant amount of MR is co-
distributed with class II molecules in the specialized anti-
gen-loading MHC II compartment (42), there is the po-
tential for Ii-CS interactions with Cys-MR, and we raise
the possibility that such interactions may occur, and thus
facilitate, the class II–Ii dissociation, simultaneously facili-
tating class II–peptide antigen binding.
Chondroitin sulfate chains occur, par excellence, on
proteoglycans in extracellular matrices (34, 43). The pres-
ence and the accessibility of Cys-MR ligands in extracellu-
lar matrices deserve investigation. Here may lie deter-
minants of the trafficking of macrophages and their
localization in pathological tissues, and also clues to the in-
teractions of MR-bearing kidney mesangial, tracheal
smooth muscle, and retinal pigment cells.
Carbohydrate sequences of the blood group family occur
widely at the surface of cells. They occur on glycoproteins
and glycolipids, and constitute a class of differentiation anti-
gen, a reflection of the pronounced differentiation-associ-
ated changes they undergo in the branching patterns of
their backbone regions and in the capping residues that
they bear in their peripheral regions (44). The sialyl-Lex
and -Lea sequences occur variously as markers of granulo-
cytes, monocytes, or subsets of lymphocytes. The sulfo-Lex
and -Lea sequences are differentially expressed on various
normal and malignant epithelial cells (45), and they may
constitute ligands that mediate interactions of cancer cells
with the selectins. In its ability to bind to the sulfo-Lea and
-Lex sequences, Cys-MR overlaps with the selectins (46),
but it differs in its preference for the nonfucosylated ana-
logues. The distribution of sulfated blood group chains on
cells of the immune system needs to be determined. It will
be interesting to investigate whether they occur on the
acidic glycoforms of glycoproteins, such as sialoadhesin or
CD45 of lymphoid tissue and the spleen, that are bound by
Cys-MR (47, 48).
So far, we have considered endogenous ligands for Cys-
MR. The repertoire of sequences recognized by this do-
main raises the possibility that certain acidic microbial
polysaccharides may be bound. Thus, it will be interesting
to determine whether, in an analogous way to the man-
nose-binding C-type lectin domains on MR, the Cys-MR
contributes to trapping of ligand-positive microbial patho-
gens, and to the delivery of ligand-positive antigens for
processing and presentation.
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